Page last updated: 2024-12-06

zaltidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

zaltidine: RN given for parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID56051
CHEMBL ID70209
SCHEMBL ID534302
SCHEMBL ID534303
SCHEMBL ID10367794
MeSH IDM0144366

Synonyms (33)

Synonym
unii-54hy424479
zaltidinum [latin]
zaltidinum
zaltidine [inn:ban]
54hy424479 ,
zaltidina
guanidine, (4-(2-methyl-1h-imidazol-4-yl)-2-thiazolyl)-
85604-00-8
zaltidina [spanish]
zaltidine
cp-57361
CHEMBL70209
2-[4-(2-methyl-1h-imidazol-5-yl)-1,3-thiazol-2-yl]guanidine
HY-15541
CS-1392
SCHEMBL534302
SCHEMBL534303
(4-(2-methylimidazol-5-yl)-2-thiazolyl)quanidine
guanidine, (4-(2-methyl-1h-imidazol-5-yl)-2-thiazolyl)-
zaltidine [inn]
2-guanidino-4-(2-methyl-4-imidazolyl)thiazole
GIMNAEMRNXUAQP-UHFFFAOYSA-N
SCHEMBL10367794
AKOS030526184
1-(4-(2-methyl-1h-imidazol-4-yl)thiazol-2-yl)guanidine
85604-00-8 (free base)
1-(4-(2-methyl-1h-imidazol-5-yl)thiazol-2-yl)guanidine
Q27261214
A914628
F84942
MS-23246
DTXSID60868921
n''-[4-(2-methyl-1h-imidazol-5-yl)-1,3-thiazol-2-yl]guanidine

Research Excerpts

Overview

Zaltidine is a new H2-receptor antagonist.

ExcerptReferenceRelevance
"Zaltidine is a new H2-receptor antagonist. "( Zaltidine: an effective but hepatotoxic H2-receptor antagonist.
Farup, PG, 1988
)
3.16
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID60730Maximum percent inhibition of acid output in penta gastrin-stimulated Heidenhain pouch dogs at a dose of 0.5 mg/kg, given intravenously (iv).1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Bioisosteric prototype design of biaryl imidazolyl and triazolyl competitive histamine H2-receptor antagonists.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID19424Partition coefficient (logD7.4)2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID59672Effective dose on oral administration was evaluated for the inhibition of acid output in penta gastrin stimulated Heidenhain pouch dogs1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Bioisosteric prototype design of biaryl imidazolyl and triazolyl competitive histamine H2-receptor antagonists.
AID88019Histamine H2 receptor antagonistic activity was evaluated in guinea pig atrium.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Bioisosteric prototype design of biaryl imidazolyl and triazolyl competitive histamine H2-receptor antagonists.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (60.00)18.7374
1990's1 (20.00)18.2507
2000's1 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.20 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (33.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]